$RGLS
Regulus Therapeutics Inc.

2014 Q4 Form 10-Q Financial Statement

#000119312514398921 Filed on November 06, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $4.219M $1.083M $6.118M
YoY Change -22.64% -82.3% 117.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.280M $2.570M $1.920M
YoY Change 74.47% 33.85% 76.15%
% of Gross Profit
Research & Development $10.47M $10.17M $7.106M
YoY Change 27.22% 43.16% 35.4%
% of Gross Profit
Depreciation & Amortization $390.0K $400.0K $370.0K
YoY Change 8.33% 8.11% 42.31%
% of Gross Profit
Operating Expenses $13.75M $12.74M $9.023M
YoY Change 35.94% 41.22% 42.3%
Operating Profit -$11.66M -$2.905M
YoY Change 301.34% -17.75%
Interest Expense $100.0K $10.00K $7.000K
YoY Change 42.86% 42.86% -93.64%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$22.17M -$9.798M -$2.169M
YoY Change 1036.92% 351.73% -61.89%
Income Tax $0.00 $0.00 -$5.000K
% Of Pretax Income
Net Earnings -$22.17M -$9.798M -$2.164M
YoY Change 1050.39% 352.77% -61.93%
Net Earnings / Revenue -525.43% -904.71% -35.37%
Basic Earnings Per Share -$0.47 -$0.23 -$0.05
Diluted Earnings Per Share -$0.47 -$0.26 -$0.07
COMMON SHARES
Basic Shares Outstanding 48.60M shares 43.41M shares 40.15M shares
Diluted Shares Outstanding 44.86M shares 41.56M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.7M $94.10M $123.9M
YoY Change 40.09% -24.05% 300.97%
Cash & Equivalents $37.33M $9.958M $33.49M
Short-Term Investments $122.4M $84.10M $90.40M
Other Short-Term Assets $742.0K $4.000M $1.300M
YoY Change -76.06% 207.69% 160.0%
Inventory
Prepaid Expenses
Receivables $300.0K $100.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $165.0M $98.02M $125.3M
YoY Change 40.76% -21.76% 264.64%
LONG-TERM ASSETS
Property, Plant & Equipment $3.568M $3.840M $3.981M
YoY Change -5.31% -3.54% 26.62%
Goodwill
YoY Change
Intangibles $1.150M $1.114M $1.145M
YoY Change 1.95% -2.71% 1.87%
Long-Term Investments
YoY Change
Other Assets $1.811M $1.038M $178.0K
YoY Change 83.49% 483.15% -91.51%
Total Long-Term Assets $6.529M $5.992M $5.304M
YoY Change 10.98% 12.97% -16.66%
TOTAL ASSETS
Total Short-Term Assets $165.0M $98.02M $125.3M
Total Long-Term Assets $6.529M $5.992M $5.304M
Total Assets $171.5M $104.0M $130.6M
YoY Change 39.34% -20.35% 220.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.188M $2.642M $1.140M
YoY Change 86.69% 131.75% 75.65%
Accrued Expenses $4.402M $3.633M $1.705M
YoY Change 46.1% 113.08% -18.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $23.40M
YoY Change
Total Short-Term Liabilities $35.19M $11.89M $13.53M
YoY Change 239.36% -12.08% 0.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $10.70M $13.90M
YoY Change -100.0% -23.02% -20.11%
Other Long-Term Liabilities $1.022M $1.142M $1.558M
YoY Change -29.95% -26.7% -91.49%
Total Long-Term Liabilities $1.022M $1.142M $1.558M
YoY Change -29.95% -26.7% -95.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.19M $11.89M $13.53M
Total Long-Term Liabilities $1.022M $1.142M $1.558M
Total Liabilities $39.47M $29.94M $36.14M
YoY Change 33.3% -17.18% -26.51%
SHAREHOLDERS EQUITY
Retained Earnings -$135.8M -$113.6M -$77.16M
YoY Change 71.67% 47.23% 44.11%
Common Stock $268.0M $43.00K $42.00K
YoY Change 637942.86% 2.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $132.0M $74.08M $94.45M
YoY Change
Total Liabilities & Shareholders Equity $171.5M $104.0M $130.6M
YoY Change 39.34% -20.35% 220.68%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$22.17M -$9.798M -$2.164M
YoY Change 1050.39% 352.77% -61.93%
Depreciation, Depletion And Amortization $390.0K $400.0K $370.0K
YoY Change 8.33% 8.11% 42.31%
Cash From Operating Activities -$11.66M -$8.800M -$4.430M
YoY Change 25.24% 98.65% -2026.09%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K -$390.0K -$340.0K
YoY Change -84.21% 14.71% -3500.0%
Acquisitions
YoY Change
Other Investing Activities -$38.81M $8.960M -$27.16M
YoY Change 529.01% -132.99% -419.53%
Cash From Investing Activities -$38.84M $8.580M -$27.49M
YoY Change 509.73% -131.21% -423.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $45.80M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 77.87M 160.0K 46.25M
YoY Change -778800.0% -99.65% 1130.05%
NET CHANGE
Cash From Operating Activities -11.66M -8.800M -4.430M
Cash From Investing Activities -38.84M 8.580M -27.49M
Cash From Financing Activities 77.87M 160.0K 46.25M
Net Change In Cash 27.37M -60.00K 14.33M
YoY Change -274.44% -100.42% 14.64%
FREE CASH FLOW
Cash From Operating Activities -$11.66M -$8.800M -$4.430M
Capital Expenditures -$30.00K -$390.0K -$340.0K
Free Cash Flow -$11.63M -$8.410M -$4.090M
YoY Change 27.52% 105.62% -1959.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48603831 shares
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33490000
CY2014Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43439562 shares
CY2014Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9959146 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.47
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6271000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43439562 shares
CY2014Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6235000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11893000
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-66000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1444000
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
187702000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2642000
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1142000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
74080000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113599000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
98023000
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4174000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3633000
CY2014Q3 us-gaap Liabilities
Liabilities
29935000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
43000
CY2014Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
10665000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104015000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1038000
CY2014Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1114000
CY2014Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
92867000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3840000
CY2014Q3 us-gaap Assets
Assets
104015000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9958000
CY2014Q3 us-gaap Short Term Investments
ShortTermInvestments
84107000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3958000
CY2014Q3 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
84140000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40552000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41787326 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.69
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5598000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41787326 shares
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6500000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10370000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1297000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
172518000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1172000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1459000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
93457000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79087000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4888000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3013000
CY2013Q4 us-gaap Liabilities
Liabilities
29608000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
42000
CY2013Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
11279000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123065000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
987000
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1128000
CY2013Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
113368000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3768000
CY2013Q4 us-gaap Assets
Assets
123065000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
96198000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3177000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
117182000
CY2013Q4 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
96181000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37367368 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19016000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3875462 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37367368 shares
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17807000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
608000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-3787000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
50390000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16745000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
57000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-16741000
us-gaap Revenues
Revenues
14115000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
512000
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
84000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16733000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13140000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
46000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
95000
us-gaap Interest And Other Income
InterestAndOtherIncome
207000
us-gaap Net Income Loss
NetIncomeLoss
-16741000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1012000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
46478000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
68000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-120000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5545000
us-gaap Share Based Compensation
ShareBasedCompensation
2524000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7062000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-34524000
us-gaap Operating Expenses
OperatingExpenses
27255000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11615000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
851000
us-gaap Interest Expense
InterestExpense
25000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
829000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46562000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
996000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2524000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21710000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
16520000
us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
947000
dei Trading Symbol
TradingSymbol
RGLS
dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001505512
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1191000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43155601 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.71
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-27853000
us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
0.80 pure
us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.0792 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0017 pure
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
310000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.46
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3762394 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Use of Estimates</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</p> </div>
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43155601 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
208000 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1120000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
614000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
52268000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34511000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-34512000
us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
9000
us-gaap Interest Paid
InterestPaid
30000
us-gaap Revenues
Revenues
3450000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
882000
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
106000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34562000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35377000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
53000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-50000
us-gaap Interest And Other Income
InterestAndOtherIncome
283000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-18000
us-gaap Net Income Loss
NetIncomeLoss
-34512000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1235000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10371000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-203000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
147000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8255000
us-gaap Share Based Compensation
ShareBasedCompensation
4710000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7849000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
9633000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1470000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9853000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
624000
us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
42000
us-gaap Operating Expenses
OperatingExpenses
38827000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-980000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
610000
us-gaap Interest Expense
InterestExpense
31000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1098000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4710000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30572000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
63074000
rgls Effect Of Ten Percent Increase Or Decrease In Volatility On Estimated Fair Value Of Convertible Notes Payable
EffectOfTenPercentIncreaseOrDecreaseInVolatilityOnEstimatedFairValueOfConvertibleNotesPayable
0.02 pure
CY2012Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2015-10-09
CY2013 us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
0.66 pure
CY2013 us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.0740 pure
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.00325 pure
CY2013 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
42000
CY2013 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
25000
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41555660 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1400848 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3041033 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40154812 shares
CY2013Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
671000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
37000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2169000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2835000
CY2013Q3 us-gaap Revenues
Revenues
6118000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2127000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2905000
CY2013Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
72000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-2164000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1917000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
9023000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000
CY2013Q3 us-gaap Interest Expense
InterestExpense
7000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
978000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7106000
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44855463 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1449212 shares
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1949096 shares
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-9798000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9798000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11583000
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43406251 shares
CY2014Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
1785000
CY2014Q3 us-gaap Revenues
Revenues
1083000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9822000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11659000
CY2014Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
86000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2569000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
12742000
CY2014Q3 us-gaap Interest Expense
InterestExpense
10000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1627000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10173000

Files In Submission

Name View Source Status
0001193125-14-398921-index-headers.html Edgar Link pending
0001193125-14-398921-index.html Edgar Link pending
0001193125-14-398921.txt Edgar Link pending
0001193125-14-398921-xbrl.zip Edgar Link pending
d780922d10q.htm Edgar Link pending
d780922dex311.htm Edgar Link pending
d780922dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20140930.xml Edgar Link completed
rgls-20140930.xsd Edgar Link pending
rgls-20140930_cal.xml Edgar Link unprocessable
rgls-20140930_def.xml Edgar Link unprocessable
rgls-20140930_lab.xml Edgar Link unprocessable
rgls-20140930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending